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Abstract: Changes in hTERT splice variant expression have been proposed to facilitate the decrease
of telomerase activity during fetal development in various human tissues. Here, we analyzed the
expression of telomerase RNA (hTR), wild type and α-spliced hTERT in developing human fetal
brain (post conception weeks, pcw, 6–19) and in young and old cortices using qPCR and correlated it
to telomerase activity measured by TRAP assay. Decrease of telomerase activity occurred early during
brain development and correlated strongest to decreased hTR expression. The expression of α-spliced
hTERT increased between pcw 10 and 19, while that of wild type hTERT remained unchanged. Lack
of expression differences between young and old cortices suggests that most changes seem to occur
early during human brain development. Using in vitro differentiation of neural precursor stem cells
(NPSCs) derived at pcw 6 we found a decrease in telomerase activity but no major expression changes
in telomerase associated genes. Thus, they do not seem to model the mechanisms for the decrease in
telomerase activity in fetal brains. Our results suggest that decreased hTR levels, as well as transient
increase in α-spliced hTERT, might both contribute to downregulation of telomerase activity during
early human brain development between 6 and 17 pcw.
Keywords: telomerase activity; brain; hTERT splice-variants; neural stem cells; hTR;
expression; development
1. Introduction
Telomerase is a ribonucleoprotein comprised of the TERT (telomerase reverse transcriptase)
protein and a TR (telomerase RNA) subunit. Its main and best understood function is telomere
maintenance. In humans, telomerase activity is high during early fetal development but down
regulated soon afterwards in most somatic cell types. However, telomerase is still active in some
adult tissues such as many immune cells, endothelium and also inducible in adult stem cells. It is also
known that the TERT protein has various telomere-independent functions (for review see [1]). One of
them seems to be a protective function of TERT protein in the brain, which could have implications for
brain ageing and neurodegenerative diseases [2,3].
In addition to wild type hTERT, various catalytically inactive splice variants of hTERT with splice
sites across the reverse transcriptase region have been described [4]. Alternative splicing of hTERT
has been found in various human cell lines and tissue types independent of telomerase activity [5,6].
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Interestingly, in many cell lines, the majority of cellular hTERT protein seems to consist of catalytically
inactive splice variants, specifically the β-splice version which can reach up to 85% of all hTERT
RNA [7]. In addition to changes in splicing patterns during development [8,9] and tumorigenesis [10],
they can also occur in response to physiological and environmental factors, such as hypoxia [11,12].
While around 21 different hTERT splice forms have been discovered across the 16 exons of hTERT,
the best studied are the α and β splice variants [5,6,9,13–16]. α-spliced hTERT consists of a 36 base
in-frame deletion [9,13] and displays a dominant negative function in cells resulting in senescence or
cell death due to telomere shortening in various cancer cell lines [5]. β-spliced hTERT modifies splicing
at exons 7 and 8 resulting in a 183 base pair deletion (exon skipping), which introduces a premature
termination codon resulting in a truncated hTERT protein without RT motifs B to E at the C-terminal
domain [9,13,16]. The ratio between wild type and β-spliced TERT was found to determine the level
of telomerase activity (TA) in 50 breast cancer cell lines [16]. While the α-splice hTERT version had
been shown to suppress telomerase activity in a dominant-negative fashion [5] there is an increasing
interest in analyzing whether various hTERT splice forms can exert non-canonical functions. For
example, it has been recently demonstrated that the β-spliced TERT protein without any catalytic
activity promoted cellular growth and was able to protect from cisplatin-induced apoptosis in breast
cancer cells [16]. Likewise, a new splice form lacking catalytic activity was able to stimulate cell
proliferation and activate Wnt signaling [6].
HTERT expression does not always correlate with telomerase activity and various non-canonical
functions for hTERT have been described recently (see [1] for review). TERT protein has been found
to reduce cellular ROS (reactive oxygen species) levels and inhibit endogenous ROS production and
apoptosis induction in cultured human cells [17–20], as well as mouse neurons [3,21–23]. Oxidative
stress has been shown to trigger nuclear export of hTERT and import into mitochondria [17,18,20,24–26].
We have shown recently that hTERT protein persists in the cytoplasm of neurons and activated
microglia, but not astrocytes of adult human brain [3]. While TERT protein levels did not change
in the hippocampus of control and Alzheimer’s brains at all levels of pathology (Braak Stage I to
VI), a greater proportion of TERT co-localized with mitochondria at Braak Stage VI compared to
controls [3]. TERT protein was also found to persist in mouse brain where it is thought to exert
protective functions [2,23,27–29]. Downregulation of TA in the adult human brain could be due to a
variety of mechanisms. It has been previously demonstrated that in rat brain, a catalytically inactive,
alternatively spliced insertion-containing TERT form predominantly persisted after TA and WT TERT
were downregulated [30]. The authors speculated that splice events could have a developmental
function in brain development [30]. Thus we were interested in investigating if α-spliced hTERT could
be the predominant hTERT splice form in adult human brain. Both the wild type and the α-spliced
version would be recognized by anti-hTERT antibodies as used in [3] recognizing the C-terminus,
which is conserved in both proteins, while it is lost in the β-splice version. For this reason, we focused
on the α-spliced version in our study.
Here, we investigated the regulation of hTR, wild type and α-spliced hTERT expression during
human fetal brain development, young and old adult frontal cortices as well as during in vitro
differentiation of neural precursor stem cells (NPSCs). We demonstrate that TA and hTR both decrease
during fetal brain development, while WT hTERT and α-spliced TERT seemed to co-exist in adult
human brain. However, while TA was also downregulated during in vitro differentiation of NPSCs no
changes in the three telomerase-related genes were found suggesting a different mechanism for the
decrease in TA compared to human fetal brain development.
2. Materials and Methods
2.1. Human Brain Tissue
The fetal brains were obtained from the MRC/Wellcome Trust Human Developmental Biology
Resource (HDBR), United Kingdom (Ethical permission for the collection and use of this material
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for research has been obtained at the Institute of Human Genetics, Newcastle and at the Institute of
Child Health, London). We used 12 human fetal brains at different stages of development (from pcw 6
until 20) with normal karyotypes (Table 1). Healthy adult brain tissues were from frontal cortices and
obtained from the Newcastle Brain Tissue Resource at Newcastle University (NBTR), United Kingdom,
after relevant informed consent from donors and in accordance with Newcastle University ethics
board and ethical approval awarded by the Joint Ethics Committee of Newcastle and North Tyneside
Health Authority (reference 08/H0906/136). All brains were assessed neuropathologically according
to published criteria [31–34] and were free of any disease-related pathologies.
Table 1. Description of brain tissues used.
Age Age group Source
Carnegie Stage 17 6 pcw HDBR
Carnegie Stage 17 6 pcw HDBR
Carnegie Stage 17 6 pcw HDBR
10 pcw 10–17 pcw HDBR
10 pcw 10–17 pcw HDBR
14 pcw 10–17 pcw HDBR
14 pcw 10–17 pcw HDBR
17 pcw 10–17 pcw HDBR
17 pcw 10–17 pcw HDBR
19 pcw 19–20 pcw HDBR
19 pcw 19–20 pcw HDBR
20 pcw 19–20 pcw HDBR
15 years old Young NBTR
20 years old Young NBTR
20 years old Young NBTR
68 years old Old NBTR
73 years old Old NBTR
78 years old Old NBTR
HDBR = Human Developmental Biology Resource; NBTR = Newcastle Brain Tissue Resource;
PCW = post-conception weeks; Gestational weeks (GW) are 2 weeks less that than pcw.
2.2. Cells and Cell Lines
SH-SY5Y neuroblastoma cells were obtained from ECACC. HeLa cervix carcinoma cells were
obtained from ATCC. Both cell lines were used as positive controls in the TRAP assay and contained
equally high amounts of telomerase activity.
2.3. Human Neural Precursor Stem Cells (hNPSCs)
The hNPSC line N1997 was isolated from forebrain of a fetus at 6 pcw with the approval from the
National Research Ethics System (15/NE/0090). Cells were grown as neurospheres and differentiated,
as described in Madgwick et al., 2015 [35]. Briefly, hNPSCs were grown on Geltrex-coated 6-well plates
in proliferation medium for 4 days, then growth medium was replaced with differentiation medium,
which was changed every other day. Cells were differentiated for 14 days and samples taken at days
0, 2, 6, 10 and 14 of differentiation. Differentiation of hNPSCs produced approximately 70% Tuj-1
expressing neurons and 30% expressing the astrocyte marker GFAP at day 14 [36]. RNA was isolated
using TRizol and TRAP lysates obtained with CHAPS buffer (TRAP kit, Roche, Switzerland).
2.4. TRAP Assay
Aliquots of the ground fetal brains were lysed with different amounts of lysis buffer depending
on the amount of the sample. Samples weighing between 1.7 mg and 4 mg were lysed with 20 µL
of CHAPS lysis buffer. Samples weighing between 4 mg and approximately 8 mg were lysed with
30–40 µL of lysis buffer. The rest of the fetal brain samples, and neural stem cell samples were
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lysed with 50 µL of lysis buffer. Total protein concentration was measured by Bradford assay
(Bio-Rad Protein Assay, Hercules, CA, USA) and absorbance at 450 nm was measured using an Omega
spectrophotometer (Omega FLUOstar, BMG Labtech, Ortenberg, Germany). Twenty-five microliters of
TeloTAGGG PCR reaction buffer and 1 µg of protein to a final volume of 50 µL in RNase free water
were used for each sample in the amplification step. Samples were diluted by 1:10 if the required the
samples were too concentrated. 100 ng of HeLa lysates was used as a positive control. The TRAP assay
was performed according to the manufacturer’s protocol (TeloTAGGG Telomerase PCR ELISA kit,
Roche, Switzerland). Absorbance at 450 nm was detected using the Omega spectrophotometer.
2.5. Quantitative PCR
RNA isolation was performed using the RNeasy Lipid Tissue kit (Qiagen, Hilden, Germany)
according to manufacturer’s protocol. QIAshredder was used for disruption and homogenisation.
RNA were eluted in 30 µL of RNase free water. Reverse transcription was performed according to
standard protocol. In brief, 1 µg of RNA was added to 1 µL of random primers (Thermo Scientific,
Waltham, MA, USA) and made up to 11 µL with RNase free water, then incubated at 75 ˝C for
7 min. Four microliters of 5ˆ First Strand Buffer (Invitrogen, Carlsbad, CA, USA), 2 µL of DTT
(0.1 M) (Invitrogen), 1 µL of RNase Inhibitor (Promega, Madison, WI, USA), 1 µL of dNTP (10 mM
stock, each) (NEB, Ipswich, MA, USA) and 1 µL of Superscript Reverse Transcriptase III (Promega)
were then added to the reaction mixture. The samples were then heated to 95 ˝C for 2 min, and
incubated at 45 ˝C for 90 min.
For each primer pair (see Table 2) samples were loaded in triplicates. For the required number of
wells on a 0.1 mL MicroAmp Fast 96-well reaction plate (Applied Biosystems, Foster City, CA, USA),
5 µL of SyBr Green (SensiFAST SYBR Hi-ROX, Bioline, London, UK), 3 µL of RNase-free dH2O, 0.5 µL
of each forward and reverse primer was added to a 0.5 mL microfuge tube. Nine microliters of the
mix was then added to each well. One microliter of sample cDNA was added to the appropriate wells.
QPCR parameters were as follows: Holding stage at 95 ˝C for 120 s, cycling stage at 95 ˝C for 5 s, then
60 ˝C for 30 s, and melt stage at 95 ˝C for 15 s, 60 ˝C for 60 s and 95 ˝C for 15 s. For hGAPDH and hTR,
cycling stage temperature was 60 ˝C. For α-spliced hTERT and WT hTERT, cycling stage temperature
was 53 ˝C. Conventional PCR was performed with hGAPDH primers using RNA from SH-SY5Y, and
6 pcw samples 1 and 2 to ensure that there was no genomic DNA contamination in the samples.
Table 2. Primers used in qPCR. * Two annealing temperatures are provided for the hTERT reverse
primer since the temperature was dependent on the respective forward primer used (WT or α hTERT).
Primer Sequence Annealing Temperature (˝C) Ref.
hGAPDH fw TGCACCACCAACTGCTTAGC 60 [37]
hGAPDH rev GGCATGGACTGTGGTCATGA 60 [37]
hTR fw GCCTTCCACCGTTCATTCTA 60 [38]
hTR rev CCTGAAAGGCCTGAACCTC 60 [38]
WT hTERT fw TGTACTTTGTCAAGGTGGATGTG 60 [14]
α-hTERT fw CTGAGCTGTACTTTGTCAAGGAC 53 [15]
hTERT rev GTACGGCTGGAGGTCTGTCAA 60/53 * [14,15]
2.6. qPCR Data Processing and Analysis
Gene expression levels were calculated using the comparative Ct method [39]. ∆Ct
(Cttarget ´ CthGAPDH) and 2´∆∆Ct (∆∆Ct = ∆Ctsample ´ ∆CtSH-SY5Y) were obtained for each technical
repeat. This method normalizes the target data to a housekeeping gene first (hGAPDH), then to
another sample (SH-SY5Y). In Figures 1 and 2, SH-SY5Y has a 2´∆∆Ct value of 1. The summary of
changes in Figure 3 are 2´∆∆Ct where the 6 pcw sample was used for normalizing. Thus, 6 pcw has a
value of 1.
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All statistics including linear regression analysis was performed using SigmaPlot 12.5 (Systat 
Software Inc., San Jose, CA, USA). qPCR data were not normally distributed, and were analyzed by 
ANOVA on ranks using the post-hoc Holm-Sidak test. Samples from 10 pcw, 14 pcw and 17 pcw 
were grouped together to increase sample numbers. Slopes for Figures 3 and 5 were generated using 
Microsoft Excel 2013. Trend lines are shown as either exponential or linear lines were used according 
to perceived fit of the line to the data points. Y intercept were shifted to ensure that the lines passed 
through 6 pcw or 0 days differentiated. 
3. Results 
3.1. Telomerase During Human Brain Development and in Adult Cortex Tissues 
We found a significant (p < 0.05) decrease in telomerase activity (TA) for every developmental 
time point in the fetal brain compared to 6 pcw (Figure 1A). TA was 0.769 ± 0.082 at 6 pcw, then 
sharply decreased to 0.292 ± 0.019 at 10 pcw, which is still positive, but low. TA below 0.2 is 
considered to be negative (TeloTAGGG Telomerase PCR ELISA kit handbook), thus, TA in fetal brain 
tissue seems to be already at negligibly low levels at 10 weeks post-conception. TA in brain samples 
from young donors was also analyzed and displayed an absorbance unit of 0.085, showing that TA 
remained negative in adult brains. 
 
Figure 1. Telomerase activity and expression of telomerase-related genes in fetal brain, young and old 
cortices. (A) Telomerase activity, mean and SD, TA at 6 pcw was significantly different from all other 
time points; (B) α-spliced hTERT, the values for 19/20 pcw are significantly different from those on 
10–17 pcw; (C) WT hTERT, (D) hTR expression at 6 pcw was significantly different from old brains. 
(B–D) are not normally distributed and have been normalised to SH-SY5Y controls and their 2−ΔΔCt set 
as 1. The box plots show mean and SD of n = 3 for the 6 pcw and 19/ 20 pcw groups, and n = 6 for the 
10–17 pcw groups. Box-plots show the median with 25% and 75% interval in the box, whiskers the 
10% and 90%. One way ANOVA (on ranks for (B–D)) and Holm-Sidak post hoc tests were performed 
to determine statistical significance. * p < 0.05. 
Figure 1. Telomerase activity and expression of telomerase-related genes in fetal brain, young and old
cortices. (A) Telomerase activity, mean and SD, TA at 6 pcw was significantly different from all other
time points; (B) α-spliced hTERT, the values for 19/20 pcw are significantly different from those on
10–17 pcw; (C) WT hTERT, (D) hTR expression at 6 pcw was significantly different from old brains.
(B–D) are not normally distributed and have been normalised to SH-SY5Y controls and their 2´∆∆Ct
set as 1. The box plots show mean and SD of n = 3 for the 6 pcw and 19/ 20 pcw groups, and n = 6 for
the 10–17 pcw groups. Box-plots show the median with 25% and 75% interval in the box, whiskers the
10% an 90%. One way ANOVA (on ranks for (B–D)) and Holm-Sidak post hoc tests were performed to
determine statistical significance. * p < 0.05.
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α-spliced hTERT expression displayed a trend towards an increase from a mean 2−ΔΔCt value of 
0.120 ± 0.018 at 6 pcw to 0.976 ± 0.181 at 19 and 20 pcw, while it increased significantly (p < 0.05) 
between 10–17 pcw and 19 and 20 pcw, from 0.331 ± 0.026 to 0.976 ± 0.031 (Figure 1B). Interestingly, 
expression then decreased again in adult human cortices, where it was expressed at comparably low 
levels as in early fetal stage (6 pcw). Thus, there seems to be transient increase in α-spliced TERT 
which is not maintained into adulthood. However, there was no significant correlation to TA. 
WT hTERT expression did not change significantly during both fetal development and in 
adulthood but showed a trend towards increase similar to the α-spliced hTERT at 19/20 pcw (Figure 1C). 
Thus, in general, it seems that WT hTERT expression seems rather constant in brain tissue during 
different ages. 
In contrast to the expression of WT and α-spliced TERT, hTR expression followed the general 
trend of decrease detected for telomerase activity in the analyzed brain tissue (Figure 1D). 
Performing a linear regression analysis we found a highly significant correlation between hTR 
amounts and telomerase activity (Figure 2, p = 0.003). Comparing the rates of change in the different 
parameters measured for brain tissue (Figure 3), α-spliced hTERT amounts increase at a higher rate 
than the decrease in hTR but did not correlate significantly with the decrease in TA. 
 
Figure 2. Regression analysis showing a significant correlation between hTR expression and 
telomerase activity. Data as shown in Figure 1A,D. 
 
Figure 3. Summary of changes in expression of telomerase-related genes in fetal brain, young and old 
cortices. Data correspond to those from Figure 1. Telomerase activity and 2−ΔΔCt of all data were 
acquired by normalizing to 6 pcw instead of SH-SY5Y (in the case of 2−ΔΔCt data), allowing fold change 
comparison of any time point with 6 pcw. Rate of change in each target over development can be 
determined from the slope of the graphs. 
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Figure 2. Regression analysis showing a significant correlation between hTR expression and telomerase
activity. Data as shown in Figure 1A,D.
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α-spliced hTERT expression displayed a trend towards an increase from a mean 2−ΔΔCt value of 
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Figure 3. Summary of changes in expression of telomerase-related genes in fetal brain, young and
old cortices. Data correspond to those from Figure 1. Telomerase activity and 2´∆∆Ct of all data were
acquired by normalizing to 6 pcw instead of SH-SY5Y (in the case of 2´∆∆Ct data), allowing fold change
comparison of any time point with 6 pcw. Rate of change in each target over development can be
determined from the slope of the graphs.
2.7. Statistical Analysis
All statistics including linear regression analysis was performed and graphs in Figures 1 and 4
created using SigmaPlot 12.5 (Systat Software Inc., San Jose, CA, USA). qPCR data were not normally
distributed, and were analyzed by ANOVA on ranks using the post-hoc Holm-Sidak test. Samples
from 10 pcw, 14 pcw and 17 pcw were grouped together to increase sample numbers. Slopes for
Figures 3 and 5 were generated using Microsoft Excel 2013. Trend lines are shown as either exponential
or linear lines were used according to perceived fit of the line to the data points. Y intercept were
shifted to ensure that the lines passed through 6 pcw or 0 days differentiated.
3. Results
3.1. Telomerase During Human Brain Development and in Adult Cortex Tissues
We found a significant (p < 0.05) decrease in telomerase activity (TA) for every developmental
time point in the fetal brain compared to 6 pcw (Figure 1A). TA was 0.769 ˘ 0.082 at 6 pcw, then sharply
decreased to 0.292 ˘ 0.019 at 10 pcw, which is still positive, but low. TA below 0.2 is considered to be
negative (TeloTAGGG Telomerase PCR ELISA kit handbook), thus, TA in fetal brain tissue seems to be
already at negligibly low levels at 10 weeks post-conception. TA in brain samples from young donors
was also analyzed and displayed an absorbance unit of 0.085, showing that TA remained negative in
adult brains.
α-spliced hTERT expression displayed a trend towards an increase from a mean 2´∆∆Ct value
of 0.120 ˘ 0.018 at 6 pcw to 0.976 ˘ 0.181 at 19 and 20 pcw, while it increased significantly (p < 0.05)
between 10–17 pcw and 19 and 20 pcw, from 0.331 ˘ 0.026 to 0.976 ˘ 0.031 (Figure 1B). Interestingly,
expression then decreased again in adult human cortices, where it was expressed at comparably low
levels as in early fetal stage (6 pcw). Thus, there seems to be transient increase in α-spliced TERT
which is not maintained into adulthood. However, there was no significant correlation to TA.
WT hTERT expression did not change significantly during both fetal development and in
adulthood but showed a trend towards increase similar to the α-spliced hTERT at 19/20 pcw
(Figure 1C). Thus, in general, it seems that WT hTERT expression seems rather constant in brain
tissue during different ages.
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3.2. In Vitro Differentiation of Neural Precursor Stem Cells (NPSCs) 
Since at early stages of brain development there is a major involvement of neural stem cells we 
determined the same parameters for brain tissues in NPSCs that had been differentiated in vitro over 
the course of 2 weeks. The neural precursor stem cell line N1997 was derived from forebrain at the 
same stage as the youngest brains (6 pcw). In vitro differentiation was performed over 2 weeks and 
aliquots taken at the indicated days. Telomerase activity showed no significant changes between 0 
and 6 days of differentiation (DD) (Figure 4A). In contrast, TA significantly decreased after 6 days 
and no TA was detected after 10 days of differentiation (p < 0.05), corresponding to a differentiated 
phenotype of NSPC derived cells after 14 days of differentiation, where the cultures would consists 
of neurons and astrocytes in a ratio of their protein amounts being around 70% from neurons and 
30% from astrocytes [36]. 
Expression of α-spliced hTERT was in general very high and comparable to that of SH-SY5Y 
neuroblastoma cells (set as 1) throughout the differentiation process (Figure 4B). Although there was 
a high heterogeneity at 2 weeks, nothing reached statistical significance. WT hTERT transcripts were 
also comparably high in relation to SH-SY5Y neuroblastoma cells (set as 1) throughout the 
differentiation process (Figure 4C). Although this result seems expected, as NPSCs from early human 
embryos should have a high expression of wild type hTERT and TA, it was surprising that it does 
not correlate to the sharp decrease in TA. After day 6, expression of hTR was also constant at all time 
points with a very low expression levels at days 0–6, and a slight trend towards an increase at longer 
differentiation times (Figure 4D). However, none of the expression kinetics determined during 
differentiation of the NPSCs correlated or could explain the decrease in TA at later days of 
differentiation. A summary of the changes is provided in Figure 5. 
 
Figure 4. Telomerase activity and expression of telomerase-related genes in neural precursor stem 
cells and their differentiated progeny. (A) Telomerase activity, mean and SD from 2 independent 
differentiation experiments with significant differences between day 6 and 14; (B) α-spliced hTERT; 
(C) WT hTERT; (D) hTR expression. (B–D) have been normalised to SH-SY5Y, where 2−ΔΔCt was set to 
1. * p < 0.05. One way ANOVA (on ranks for (B–D)) and Holm-Sidak post hoc test was performed was 
performed on these data. The bars show mean and SD of n = 2 (independent qPCR runs) for all groups 
in (B–D). 
Figure 4. Telomerase activity and expression of telomerase-related genes in neural precursor stem
cells and their differentiated progeny. (A) Telomerase activity, mean and SD from 2 independent
differentiation experiments with significant differences between day 6 and 14; (B) α-spliced hTERT;
(C) WT hTERT; (D) hTR expression. (B–D) have been normalised to SH-SY5Y, where 2´∆∆Ct was set to
1. * p < 0.05. One way ANOVA (on ranks for (B–D)) and Holm-Sidak post hoc test was performed was
performed on these data. The bars show mean and SD of n = 2 (independent qPCR runs) for all groups
in (B–D).Genes 2016, 7, 27 8 of 14 
 
Figure 5. Summary of changes in expression of telomerase-related genes in neural precursor stem 
cells and their differentiated progeny. Data correspond to those from Figure 4. Telomerase activity 
and 2−ΔΔCt of all data were acquired by normalizing to 0 days differentiated instead of SH-SY5Y (in the 
case of 2−ΔΔCt data), allowing fold change comparison of any time point with 0 days differentiated. 
Rate of change in each target over development can be determined from the slope of the graphs. 
In conclusion, our data show that TA is significantly downregulated during fetal brain 
development, as well as during in vitro differentiation of human NSPCs. However, expression levels 
and kinetics of telomerase related genes did not correspond between both types of experiments. Thus, 
in vitro differentiation experiments of NPSCs do not model the mechanisms of downregulation of 
telomerase activity in early human brain development. 
4. Discussion 
In this study we analyzed the expression of telomerase activity, as well as the expression of 
different telomerase associated genes such as α-spliced hTERT, WT hTERT and hTR during fetal 
brain development and in vitro differentiation of neural stem/progenitor cells. Human brain 
development begins during the third gestational week (GW) with the differentiation of the neural 
progenitor cells, and lasts into adulthood. By the end of the embryonic period at eight gestational 
weeks (corresponding to six post conception weeks) the basic brain structures are established and the 
major compartments defined [40]. During fetal development there is rapid growth and development 
of both cortical and subcortical structures. Neuron production in humans begins at embryonic week 
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Figure 5. Su ary of changes in expression of telomerase-related genes in neural precursor stem cells
and their differentiated progeny. Data correspond to those from Figure 4. Telomerase activity and
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case of 2´∆∆Ct data), allowing fold change comparison of any time point ith 0 ays iffere tiate .
ate f c a e i eac tar et er e el e t ca e eter i e fro the slope of the graphs.
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In contrast to the expression of WT and α-spliced TERT, hTR expression followed the general
trend of decrease detected for telomerase activity in the analyzed brain tissue (Figure 1D).
Performing a linear regression analysis we found a highly significant correlation between hTR
amounts and telomerase activity (Figure 2, p = 0.003). Comparing the rates of change in the different
parameters measured for brain tissue (Figure 3), α-spliced hTERT amounts increase at a higher rate
than the decrease in hTR but did not correlate significantly with the decrease in TA.
3.2. In Vitro Differentiation of Neural Precursor Stem Cells (NPSCs)
Since at early stages of brain development there is a major involvement of neural stem cells we
determined the same parameters for brain tissues in NPSCs that had been differentiated in vitro over
the course of 2 weeks. The neural precursor stem cell line N1997 was derived from forebrain at the
same stage as the youngest brains (6 pcw). In vitro differentiation was performed over 2 weeks and
aliquots taken at the indicated days. Telomerase activity showed no significant changes between 0
and 6 days of differentiation (DD) (Figure 4A). In contrast, TA significantly decreased after 6 days
and no TA was detected after 10 days of differentiation (p < 0.05), corresponding to a differentiated
phenotype of NSPC derived cells after 14 days of differentiation, where the cultures would consists of
neurons and astrocytes in a ratio of their protein amounts being around 70% from neurons and 30%
from astrocytes [36].
Expression of α-spliced hTERT was in general very high and comparable to that of SH-SY5Y
neuroblastoma cells (set as 1) throughout the differentiation process (Figure 4B). Although there was a
high heterogeneity at 2 weeks, nothing reached statistical significance. WT hTERT transcripts were also
comparably high in relation to SH-SY5Y neuroblastoma cells (set as 1) throughout the differentiation
process (Figure 4C). Although this result seems expected, as NPSCs from early human embryos should
have a high expression of wild type hTERT and TA, it was surprising that it does not correlate to
the sharp decrease in TA. After day 6, expression of hTR was also constant at all time points with a
very low expression levels at days 0–6, and a slight trend towards an increase at longer differentiation
times (Figure 4D). However, none of the expression kinetics determined during differentiation of the
NPSCs correlated or could explain the decrease in TA at later days of differentiation. A summary of
the changes is provided in Figure 5.
In conclusion, our data show that TA is significantly downregulated during fetal brain
development, as well as during in vitro differentiation of human NSPCs. However, expression levels
and kinetics of telomerase related genes did not correspond between both types of experiments. Thus,
in vitro differentiation experiments of NPSCs do not model the mechanisms of downregulation of
telomerase activity in early human brain development.
4. Discussion
In this study we analyzed the expression of telomerase activity, as well as the expression of
different telomerase associated genes such as α-spliced hTERT, WT hTERT and hTR during fetal brain
development and in vitro differentiation of neural stem/progenitor cells. Human brain development
begins during the third gestational week (GW) with the differentiation of the neural progenitor cells,
and lasts into adulthood. By the end of the embryonic period at eight gestational weeks (corresponding
to six post conception weeks) the basic brain structures are established and the major compartments
defined [40]. During fetal development there is rapid growth and development of both cortical
and subcortical structures. Neuron production in humans begins at embryonic week seven, until
completion in the middle of gestation (GW 20). After week seven, neurons migrate and begin to form
major network structures. At the beginning of neuron production before embryonic week seven, there
is a rapid expansion of the neural stem and precursor pool by symmetric division [40]. This is followed
by asymmetrical division of NPSCs and cortical neurogenesis is complete in humans by around week
15. From then on neurons migrate in a radial manner from the ventricular zone (VZ) in the center of
the brain where the stem cells are located out to the developing neocortex. After reaching their target
Genes 2016, 7, 27 9 of 14
region in the cortex, the young neurons mature further by forming axons and dendrites in order to
form networks and transmit information [40].
A decrease of telomerase activity in fetal human brains from GW 10 (pcw 8) after gestational
week 16 has been described previously [8]. We detected high levels of TA at 6 pcw, which corresponds
to eight gestational weeks. At this stage there is a high amount of rapidly dividing neuronal stem
and progenitor cells present in the developing brain [40,41]. At 10 pcw TA was still detectable, but
disappeared between 14 and 17 pcw corresponding well to Ulaner’s results [8] and the onset of the
neuronal maturation process [40].
The ratio of proliferative NPSCs to differentiated cells (neurons and glial cells) shifts over the
course of the development of embryonic and fetal brain with a large amount of symmetrically dividing
NPSCs between 4 to 6 pcw [40]. Thus, we suggest that the early developing brain predominantly
contains of telomerase positive actively dividing NPSCs. This is consistent with the high TA we
observed in brain tissue at 6 pcw. As neurogenesis progresses, progenitors progressively undergo
asymmetric division differentiating into mature brain cells. Consequently, the expansion of the
progenitor pool gradually slows [42]. Thus, the decrease in TA during brain development could
be attributed to the progressive expansion of the post-mitotic neuronal population and the relative
decrease of the NPSC population.
Human astrocytes from old brains, as well as astrocytes in mixed mouse cultures, did not express
TERT protein while neurons from the same cultures were positive for TERT protein and positive for
telomerase activity at least one week during in vitro culture [3], presumably coinciding with a neuronal
maturation process.
Importantly, we found that the decrease in TA correlated strongly with a decrease in hTR
expression for the corresponding time points. Although hTR expression has been suggested to be
ubiquitous in most cell types [43], it has been demonstrated that repression of hTR expression resulted
in a rapid growth arrest and a dramatic decrease in TA in MCF7 cancer cells [44]. The authors found
that reduction in hTR stimulated ATR activity and elicited a p53/CHK1-dependent cell cycle arrest
independent of DNA damage. Others have identified transcriptional repressors of hTR expression
such as mdm2 [45]. In addition, in genetic diseases, such as Dyskeratosis congenita, caused by either
mutations in the hTR gene or defects in dyskerin result in diminished hTR levels that in turn limit
telomerase activity and telomere length [46,47].
In contrast, Ulaner and co-authors did not find any changes of hTR expression in fetal heart and
kidney tissue using a conventional PCR method until 21 gestational weeks (the last time point fetal
tissue can be obtained from clinically indicated abortions) although TA was severely downregulated
between post-conception weeks 9 and 13, respectively, in these two tissues (Table 3) [9]. Thus, it seems
that hTR had no major contribution in the downregulation of TA in these two tissues. That could mean
that different mechanisms are employed for downregulation of TA in different tissue types and the
downregulation of hTR as a mechanism to downregulate TA might be more brain specific. Not much
is known about hTR expression or its regulation in brain cells (predominantly neurons and astrocytes).
Stimulation of TA, hTERT and hTR had been found by the oncofetal protein Pax8 in human glioma [48].
Pax genes play a role in early brain development [49] and their deregulation has been linked cancer
types, such as astrocytoma and gliomas.
Correlation of TA with wild type, α-spliced and β-spliced hTERT differs across human fetal heart,
liver and kidney development [8,9] (see also Table 3). In fetal kidney, Ulaner and co-authors found that
WT hTERT was maintained until 21 gestational weeks (19 pcw) while both TA and WT hTERT were
abolished by 15 and 16 weeks, respectively. α-spliced TERT was not detected by week nine, while,
from week 20 onwards, only the β-splice version was expressed [9]. Thus, a downregulation of TA
correlated best with the disappearance of the WT hTERT without any direct evidence of splice product
expression being involved.
Genes 2016, 7, 27 10 of 14
Table 3. Comparison of telomerase activity and expression of telomerase-related genes. Expression of
hTR, WT hTERT and α-spliced hTERT in fetal heart, kidney and liver refer to data from [8,9] while
data for brain are from this study. Numbers correspond to post-conception weeks at which hTR, WT
hTERT or α-spliced hTERT were downregulated. PCW is two weeks more than the gestational weeks
shown in [8,9].
Tissue Decrease of TA(PCW)
hTR expression
(PCW)
WT hTERT
expression (PCW)
α-spliced hTERT
expression (PCW)
Heart 11 maintained 11 Not detected
Kidney 15 maintained 16 9
Liver, Lung, Spleen maintained maintained maintained maintained
Brain 17
Downregulated
from 6 towards
19/20
19/20 Increased from 6towards 19/20
In contrast, in the fetal heart, TA, WT andα-spliced hTERT were all simultaneously downregulated
by gestational week 13/pcw 11 [9]. In liver, however, TA was maintained over development with WT
TERT and α-spliced hTERT being present [9]. Maintenance of TA directly correlated with telomere
maintenance in liver, while in heart and kidney it decreased after TA was downregulated [9]. TA
was also maintained in other tissues until gestational weeks 21 (19 pcw) of fetal development in lung,
spleen, and testis while it was lost earlier in heart, brain and kidney [8]. This is most likely due to the
fact that human adult liver tissue still possesses TA [50], adult spleen contains telomerase positive
lymphocytes while in lung tissue from adults no TA was found [51].
NSPCs
Neural stem cells emerge very early during embryonic development and produce all of the
different cells of the brain and central nervous system [40]. In order to establish how much neural
precursor stem cells (NPSCs) contributed to TA in the development of early gestational brains, we
used primary NPSCs from forebrain derived at 6 pcw. It is well known that NPSCs differentiate into
various cell types of the brain, predominantly neurons and astrocytes with neurogenesis preceding
astrogenesis [41,42]. In vitro differentiation of NPSCs usually generates a mix of neurons (70%) and
astrocytes (30%) after two weeks [36]. During the differentiation, TA decreased late in differentiation,
after 6 days. Surprisingly, TA was higher in the brain tissue from 6 pcw compared to the NPSCs
derived from a similar time point. This was most likely caused by an extensive in vitro expansion
of these NPSCs during their in vitro cultivation via neurospheres prior to their differentiation [35],
exhausting some of the stem and progenitor cell potential including telomerase activity. However,
the TA was comparable to that shown by Zhang et al. in primary NPSCs derived from gestational
week 12 [52].
We did not find any changes in the expression of telomerase-related genes that could explain
the decrease in telomerase activity during the in vitro differentiation process of hNPSCs. This result
suggests that brain development in vivo might involve different mechanisms of downregulation of
telomerase activity than in NPSCs during in vitro differentiation. However, the downregulation of TA
in vitro in human NPSCS is comparable to that found during in vitro culture of mouse neuronal cells
from embryonic day 15 that declined within the same time frame (after day eight and undetectable at
day 14) [3]. However, the exact mechanisms for this downregulation of TA remain elusive.
It is known that a decrease in telomerase activity correlates to differentiation of human embryonic
stem cells (hESCs) [53]. We demonstrated previously that in spontaneous differentiation of hESCs
over 20 days telomerase activity is downregulated towards the end of the differentiation period.
This is preceded by a strong decrease in the expression of both telomerase genes after day seven of
differentiation, and might be partly due to promoter modifications for hTERT and hTR [53]. This
kinetics was different from the one we show here in NPSCs where TA is downregulated without
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changes in the analyzed telomerase-related genes. Radan and colleagues showed that hTERT splicing
pattern rapidly induced spontaneous hESC differentiation emphasizing the importance of specific
ratios of different hTERT splice products for high telomerase activity that is necessary for indefinite
proliferation of human ESCs [12].
In general, telomerase activity is regulated by many different endogenous and exogenous factors
(for review see [54]). Downregulation of telomerase activity during differentiation of stem cells is
rather well documented [55], however in vitro differentiation of NPSCs did not model the expression
kinetics of telomerase-related genes during downregulation of telomerase activity.
5. Conclusions
In conclusion, the main finding of our study is that telomerase activity is downregulated between
pcw 6 and 14/17 during human fetal brain development. Our data suggest that a strong decrease in
hTR expression might causally contribute to the downregulation of telomerase activity. In addition,
both hTERT variants (wild type and α-spliced hTERT) seem to co-exist in neurons. It would be
interesting to determine whether α-spliced hTERT is able to exert a protective function similar to those
demonstrated for other hTERT splice versions previously [6,16].
Furthermore, our results also suggest that downregulation of TA in NPSCs in vitro does not seem
to be regulated by the same mechanisms as during brain development in vivo.
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